Saharsh Davuluri takes helm at Neuland Laboratories as CDMO accelerates push into commercial NCE contracts

Neuland Laboratories Limited (NSE: NEULANDLAB; BSE: 524558), a Hyderabad-based contract development and manufacturing organisation specialising in complex active pharmaceutical ingredients, has named Saharsh Davuluri as Chief Executive Officer and Managing Director, effective April 1, 2026. The appointment marks a generational shift in leadership at a company that has tripled its contract services revenues over the past three years, driven by a deliberate pivot away from generic bulk drugs and toward high-value new chemical entity manufacturing for global innovator clients. Saharsh, who has spent more than 18 years at Neuland Laboratories, succeeds his father Sucheth Davuluri, who transitions to the role of Executive Vice Chairman. The timing is not incidental: Neuland Laboratories is entering what management describes as an aggressive capacity expansion phase, with multiple commercial NCE contracts and peptide manufacturing deals expected to land over the next 12 to 24 months.

What does the leadership transition at Neuland Laboratories mean for its CDMO growth strategy and NCE contract pipeline?

The shift from Sucheth Davuluri to Saharsh Davuluri is not a clean break but a relay handoff, and the distinction matters for how investors read this announcement. Sucheth architected the transition away from Neuland Laboratories’ legacy generic API business, building credibility with global innovator companies through consistent process chemistry delivery and a clean regulatory track record across 18 US FDA inspections. Saharsh, who has led the company’s transformation into an NCE-focused drug substance CDMO, now inherits a business with operational momentum and the mandate to convert that momentum into commercial scale.

The strategic intent is clear: Neuland Laboratories wants to be among the top five API-focused CDMOs globally within the next decade. That is an ambitious target for a company with a market capitalisation of approximately Rs 15,000 to Rs 17,000 crore, competing against much larger Western and Asian CDMO platforms. But the company’s growth thesis rests on a narrower, more defensible wedge than scale alone. Its differentiation lies in process chemistry complexity, development speed, and what Saharsh describes as consistent CMC delivery. In an environment where global pharma companies are under increasing pressure to diversify supply chains away from a small number of dominant API sources, a mid-sized Indian CDMO with a strong regulatory track record and deep process expertise is a logical destination for new commercial mandates.

How has Neuland Laboratories grown its contract services revenues and what is driving new commercial manufacturing wins?

Neuland Laboratories has tripled its contract services revenues over the past three years, a performance that reflects a structural shift in the company’s business mix rather than a cyclical uplift. The custom manufacturing solutions segment, which covers NCE work for innovator clients, has displaced generic drug substances as the primary growth engine. The company currently holds more than 20 commercial contracts across APIs and intermediates, supported by three US FDA-inspected manufacturing facilities and a 40,000 square foot research and development facility with 1,218 kilolitres of installed reactor capacity.

The recent Q2 FY26 results illustrated just how sharp this pivot has become. Revenue reached Rs 514 crore in the September 2025 quarter, up 65 percent year on year, with net profit rising nearly 195 percent to Rs 97 crore. The company has also filed over 1,000 drug master files globally, maintaining a dual revenue base across NCE manufacturing and its legacy generic drug substance business that serves the broader generics industry. That generic base, while lower margin, provides balance-sheet stability and manufacturing utilisation that underpins the CDMO investment programme.

Why is peptide manufacturing capacity expansion central to Neuland Laboratories’ next phase of commercial growth?

Peptides have become a defining battleground in the global CDMO market, driven by the commercial explosion of GLP-1 receptor agonists and an expanding pipeline of peptide-based drug candidates in oncology, metabolic disease, and rare conditions. Neuland Laboratories has committed to a four-phase expansion of commercial peptide capacity and invested in a new commercial-scale peptide facility in 2026. This positions the company at an inflection point in a market where capacity constraints have left major innovator companies scrambling for qualified, FDA-compliant manufacturing partners outside the handful of dominant Western CDMO platforms.

The opportunity is real, but so is the execution risk. Peptide manufacturing is technically demanding, capital intensive, and subject to strict regulatory oversight at every scale-up stage. Neuland Laboratories’ competitive advantage here lies not simply in having the reactors, but in a development team with a track record of accelerating timelines through parallel development strategies. Winning peptide contracts at commercial scale requires more than capacity; it requires the ability to solve complex synthesis challenges under CMC timelines that innovator clients increasingly treat as non-negotiable.

How does Neuland Laboratories’ manufacturing infrastructure compare to global CDMO peers seeking complex API contracts?

Three US FDA and EU GMP-compliant facilities in India, 1,218 kilolitres of combined reactor capacity, and a clean inspection record across 18 US FDA audits form the regulatory backbone of Neuland Laboratories’ CDMO proposition. A new dedicated research and development process development centre in Hyderabad is also in the process of opening, which will materially expand early-stage development throughput and allow the company to engage with innovator clients at an earlier point in the drug development cycle. Earlier engagement typically translates into stickier long-term commercial relationships.

Compared to larger CDMO platforms such as Lonza, Samsung Biologics, or WuXi AppTec, Neuland Laboratories operates at a fraction of the scale. Its advantage is not breadth but depth: a focused API specialisation, a curated client base of biotech and big pharma innovators, and a manufacturing team whose institutional knowledge in process chemistry is difficult to replicate quickly. For mid-sized biotech companies seeking a reliable, quality-first commercial manufacturing partner for complex small molecules or peptides, Neuland Laboratories’ profile is increasingly compelling.

What are the execution and competitive risks Saharsh Davuluri faces as he takes charge of Neuland Laboratories’ expansion plan?

The risks embedded in Neuland Laboratories’ growth plan are worth examining alongside the opportunity. First, the company’s revenue trajectory has not been uniformly linear. Q1 FY26 was a difficult quarter, with net profit declining sharply to Rs 14 crore on revenue of Rs 293 crore, a reminder that NCE contract work can be lumpy and timing-sensitive. Large commercial manufacturing programmes are subject to customer approval timelines, regulatory milestones, and patient recruitment cycles, all of which lie outside Neuland Laboratories’ direct control. The company has acknowledged that additional NCE contracts are conditional on pending customer approvals.

Second, the CDMO market has attracted significant capital investment globally, and competition for complex API mandates is intensifying. European CDMOs are investing in Indian manufacturing partnerships. Chinese API manufacturers, despite geopolitical headwinds, retain formidable cost advantages in certain categories. Indian peers such as Divi’s Laboratories Limited, Laurus Labs Limited, and Granules India Limited are all competing for overlapping client segments. Saharsh Davuluri’s central challenge will be to convert the company’s process chemistry reputation into a sustained pipeline of commercial contracts that offsets the revenue concentration risk inherent in NCE-heavy business models.

Third, there is a capital allocation question. A four-phase peptide capacity expansion, a new R&D centre, and the doubling of process development capabilities represent substantial concurrent investments. Neuland Laboratories has maintained a relatively conservative balance sheet, and its operating cash generation has been strong in recent periods. But sustaining that discipline while funding an aggressive expansion will require careful sequencing and customer commitment visibility before capital is deployed.

How is the NEULANDLAB stock performing and does the current valuation reflect the company’s CDMO transition story?

Neuland Laboratories shares have had a turbulent 12 months heading into this announcement. The stock touched a 52-week high of Rs 19,747 before retreating sharply to a 52-week low of approximately Rs 10,400, a drawdown of nearly 47 percent at its worst. As of late March 2026, the stock was trading in the Rs 13,000 to Rs 13,500 range, roughly 30 to 33 percent below its peak. The market capitalisation at these levels stands at approximately Rs 15,000 to Rs 17,000 crore, with a trailing price-to-earnings ratio in the range of 57 to 70 times, depending on the trailing period used. That is a significant premium to the broader Indian pharmaceutical index, which reflects both the market’s recognition of Neuland Laboratories’ CDMO transition credentials and its impatience with the quarterly earnings volatility that NCE-heavy models tend to produce.

The Q3 FY26 results, which showed a 60 percent decline in net profit year on year despite a 10 percent revenue gain, appear to have contributed to near-term sentiment pressure. The consensus analyst target price from available coverage suggests upside potential of around 30 to 40 percent from current levels, implying that institutional investors broadly accept the CDMO growth narrative but are waiting for cleaner quarterly execution before re-rating. The CEO transition announcement on its own is unlikely to be a near-term catalyst; its significance is more structural, confirming the company’s strategic direction and providing a focal point for Saharsh Davuluri’s five-year execution agenda.

Key takeaways: What the Neuland Laboratories CEO transition means for investors, competitors, and the Indian CDMO sector

• Saharsh Davuluri assumes the CEO and MD role at Neuland Laboratories immediately, succeeding Sucheth Davuluri, who moves to Executive Vice Chairman. The succession is a planned transition within a family-controlled business, not a strategic pivot.
• Contract services revenues have tripled over three years, driven by a deliberate shift from generic API manufacturing to NCE-focused custom manufacturing for global innovator clients across biotech and big pharma.
• A four-phase commercial peptide capacity expansion and a new Hyderabad R&D centre are the centrepiece capital programmes under Saharsh’s leadership, targeting a market segment where CDMO capacity constraints are acute.
• The company’s ambition to rank among the top five API-focused CDMOs globally within a decade is directionally credible given its process chemistry depth, but requires sustained commercial contract wins that are currently contingent on customer approvals.
• Neuland Laboratories’ NEULANDLAB stock is trading roughly 30 to 33 percent below its 52-week high, with recent quarterly profit volatility reflecting the lumpiness of NCE contract timing rather than structural deterioration.
• Execution risk is real: Q1 FY26 and Q3 FY26 both produced sharp profit declines despite revenue growth, underscoring the earnings sensitivity of an NCE-heavy model to contract milestone timing.
• Indian CDMO peers including Divi’s Laboratories Limited, Laurus Labs Limited, and Granules India Limited are competing for overlapping mandates, making Neuland Laboratories’ process chemistry differentiation and regulatory track record its primary competitive moat.
• The geopolitical environment favours Indian API CDMOs as global pharma companies accelerate supply chain diversification away from China, but capturing that shift requires proven regulatory compliance at commercial scale, an area where Neuland Laboratories holds a verified advantage.
• With more than 20 active commercial contracts, three FDA-inspected facilities, and 1,000-plus global DMF filings, Neuland Laboratories has built a credible commercial infrastructure that Saharsh inherits at an opportune moment in the CDMO market cycle.
• The next 12 to 24 months will be the critical test: if the pending NCE and peptide contracts materialise, the leadership transition narrative will be validated. If approvals are delayed, quarterly earnings pressure could weigh on the stock until the pipeline converts.